Continuous Erector Spinae Block for Post Analgesia in Pediatric Patients

Continuous Erector Spinae Plane Local Anesthetic Infusion for Postoperative Analgesia in Pediatric Patients Undergoing Nephrectomy: Randomized Controlled Study

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04613830

Enrollment

Registered

2020-11-03

Start date

2020-11-20

Completion date

2022-12-01

Last updated

2023-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Cancer

Brief summary

The aim of this study is to evaluate the analgesic efficacy of erector spinae plane block in pediatric cancer patients undergoing open nephrectomy

Detailed description

* Sixty patients will be included in this prospective randomized study. The patients will be allocated into two groups: the ESPB group (group E, n = 30) and the tramal group (group T, n =30). * All patients will receive standard general anesthesia. Ultrasound-guided ESPB will be performed to group erector spinae plane block

Interventions

DRUGBupivacaine Hydrochloride

The patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. then injecte bupivacaine hydrochloride

DRUGTramadol hydrochloride

Patients in group Tramadol will intravenously administrate dose of 1 mg/kg/8hr tramal to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

2 Years to 7 Years

Healthy volunteers

Inclusion criteria

* Physical status ASA II. * Patients (age 2-7yrs) scheduled for open nephrectomy for malignant kidney tumors

Exclusion criteria

* History of psychological disorders. * Known sensitivity or contraindication to local anesthetics. * Localized infection at the site of block. * patients with coagulopathy or an (INR ≥ 2)

Design outcomes

Primary

Measure	Time frame	Description
total amount of opioid consumption in milligram	48 hours	total amount of opioid consumption in the frist 48hours postoperative

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026